STOCK TITAN

Mentari Therapeutics (MTRI) Net Income by Year

MTRI NASDAQ

Mentari Therapeutics, Inc. reported a net loss of $12.6M in fiscal year 2026. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q2 FY2026 through Q1 FY2027, the same line adds up to a $13.2M net loss. The table below carries 7 fiscal years, from 2020 to 2026, and the quarters Mentari Therapeutics, Inc. has filed alongside them.

FY2026 annual
Net Income -$12.6M
YoY n/m
5Y CAGR n/m

Ticker history: INM became MTRI (Mentari Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View INM history.

Source SEC Filings Latest period Q1 FY2027, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

MTRI Net Income by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY26FilingFY25FilingFY24FilingFY23FilingFY22FilingFY21FilingFY20Filing
Net Income-$13.2M-$12.6Mn/m-$8.2Mn/m-$7.7Mn/m-$7.9Mn/m-$18.6Mn/m-$10.2Mn/m-$8.9M

TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings.

MTRI Net Income by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ1'27FilingQ4'26FilingQ3'26FilingQ2'26FilingQ1'26FilingQ4'25FilingQ3'25FilingQ2'25FilingQ1'25FilingQ4'24FilingQ3'24FilingQ2'24Filing
Net Income-$2.3Mn/m-$5.8Mn/m-$3.0Mn/m-$2.0Mn/m-$1.7Mn/m-$1.8Mn/m-$2.1Mn/m-$2.6Mn/m-$1.7Mn/m-$1.9Mn/m-$1.7Mn/m-$1.5Mn/m

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Mentari Therapeutics, Inc. financials

Frequently Asked Questions

Mentari Therapeutics, Inc. reported a net loss of $12.6M in fiscal year 2026.

Mentari Therapeutics, Inc. (MTRI) reported a $8.2M net loss in fiscal year 2025 and a $12.6M net loss in fiscal year 2026. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Mentari Therapeutics, Inc. (MTRI) reported a $13.2M net loss over the trailing 12 months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings.

Across the 7 fiscal years this page covers, Mentari Therapeutics, Inc. (MTRI) net income went from -$8.9M in fiscal year 2020 to -$12.6M in fiscal year 2026.

Mentari Therapeutics, Inc. (MTRI) reported -$2.3M in net income in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Mentari Therapeutics, Inc. (MTRI) reported on that line in every period on record.